The bioadaptor proved superior to contemporary drug-eluting stents (DES) in patients undergoing percutaneous coronary intervention (PCI) according to the INFINITY-SWEDEHEART trial, with results presented by David Erlinge, MD, PhD, at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC on Monday.